keyword
MENU ▼
Read by QxMD icon Read
search

early hepatocellular carcinoma

keyword
https://www.readbyqxmd.com/read/29242604/ribosomal-protein-s15a-promotes-tumor-angiogenesis-via-enhancing-wnt-%C3%AE-catenin-induced-fgf18-expression-in-hepatocellular-carcinoma
#1
Pengyi Guo, Yi Wang, Chunxiu Dai, Chonglin Tao, Fang Wu, Xiaozai Xie, Haitao Yu, Qiandong Zhu, Junjian Li, Longyun Ye, Fuxiang Yu, Yunfeng Shan, Zhengping Yu, Renumathy Dhanasekaran, Rongyuan Zheng, Gang Chen
Ribosomal protein s15a (RPS15A) plays a promotive role in the mRNA/ribosome interactions during early translation. Our previous study has found that inhibiting RPS15A expression can decrease proliferation and induce cell cycle arrest in hepatocellular carcinoma (HCC) cell lines. However, the mechanism underlying the involvement of RPS15A in HCC pathogenesis and the clinical significance of RPS15A expression remain unclear. In this study, an evaluation of RPS15A expression in 110 surgically resected HCCs and matched tumor-adjacent normal tissues revealed an overexpression of RPS15A in HCC, which was correlated with worse survival...
December 15, 2017: Oncogene
https://www.readbyqxmd.com/read/29238703/characterization-of-alpha-fetoprotein-effects-on-dendritic-cell-and-its-function-as-effector-immune-response-activator
#2
Jeremiah Suryatenggara, Heri Wibowo, Wahyuni Lukita Atmodjo, George Mathew
Tumor antigen alpha-fetoprotein (AFP) can promote immune tolerance toward tumor cells by inducing regulatory functions of the immune system. The purpose of this study was to characterize the effects of AFP on dendritic cells (DC) in their antitumor immune response stimulation and subsequent immune tolerance toward tumor cells. Monocytes were cultured in medium with GM-CSF and IL-4 and incubated for 6 days to generate immature DC (imDC). AFP was added into the treatment group at the beginning of the monocyte-derived DC culture...
2017: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/29237909/change-of-circulating-antibodies-against-cd25-derived-peptide-antigen-in-hepatocellular-carcinoma
#3
Jiaxin Wang, Yangchun Xu, Huan Zhao, Xuan Zhang
AIMS: Several studies have shown altered levels of plasma anti-CD25 antibodies in patients with malignancy in lung, esophagus and breast. The present study was thus designed to test whether circulating anti-CD25 antibody levels were changed in hepatocellular carcinoma (HCC). METHODS: An enzyme-linked immunosorbent assay (ELISA) was developed in-house to detect plasma IgG antibodies to CD25-derived linear peptide antigens in 122 patients with HCC and 121 control subjects...
2017: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/29237235/efficacy-and-safety-of-everolimus-with-reduced-tacrolimus-in-living-donor-liver-transplant-recipients-12-month-results-of-a-randomized-multicenter-study
#4
Long-Bin Jeng, Sung Gyu Lee, Arvinder Singh Soin, Wei-Chen Lee, Kyung-Suk Suh, Dong Jin Joo, Shinji Uemoto, Jaewon Joh, Tomoharu Yoshizumi, Horng-Ren Yang, Gi-Won Song, Patricia Lopez, Jossy Kochuparampil, Carole Sips, Shuhei Kaneko, Gary Levy
In a multicenter, open-label, study, 284 living-donor liver transplant patients were randomized at 30±5 days post-transplant to start everolimus+reduced tacrolimus (EVR+rTAC) or continue standard tacrolimus (TAC Control). EVR+rTAC was non-inferior to TAC Control for the primary efficacy endpoint of treated BPAR, graft loss or death at 12 months post-transplant: difference -0.7% [90%CI -5.2%, 3.7%]; p<0.001 for non-inferiority. tBPAR occurred in 2.2% and 3.6% of patients, respectively. The key secondary endpoint, change in estimated GFR from randomization to month 12, achieved non-inferiority (p<0...
December 13, 2017: American Journal of Transplantation
https://www.readbyqxmd.com/read/29233685/contrast-enhanced-ultrasound-in-mixed-hepatocellular-cholangiocarcinoma-case-series-and-review-of-the-literature
#5
Yi Dong, Andreas Teufel, Jörg Trojan, Annalisa Berzigotti, Xin Wu Cui, Christoph F Dietrich
BACKGROUND: Mixed hepatocellular cholangiocarcinoma is a rare form of primary liver cancer. AIMS: The aim of this study is to report the results of the use of contrast enhanced ultrasound in a series of patients with confirmed mixed hepatocellular cholangiocarcinoma and to provide an updated literature review. METHODS: Between January 2012 and October 2016, 25 Asian patients with confirmed mixed hepatocellular cholangiocarcinoma were included in this bicentric retrospective analysis...
November 24, 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/29230127/intraarterial-liver-directed-therapies-the-role-of-interventional-oncology
#6
REVIEW
Jenson Ma, Juan Martin Gimenez, Tyler Sandow, Daniel Devun, David Kirsch, Paul Gulotta, Patrick Gilbert, Dennis Kay
Background: Since the early 1990s, the minimally invasive image-guided therapies used in interventional oncology to treat hepatocellular carcinoma have continued to evolve. Additionally, the range of applications has been expanded to the treatment of hepatic metastases from colorectal cancer, neuroendocrine tumors, cholangiocarcinoma, breast cancer, melanoma, and sarcoma. Methods: We searched the literature to identify publications from 1990 to the present on various image-guided intraarterial therapies and their efficacy, as well as their role in the management of primary and secondary liver malignancies...
2017: Ochsner Journal
https://www.readbyqxmd.com/read/29228649/combination-of-dual-serum-fluorescence-afp-and-hepatic-function-tests-is-valuable-to-identify-hcc-in-afp-elevated-liver-diseases
#7
Ting Wang, Kun-He Zhang, Piao-Ping Hu, Qin-Si Wan, Fang-Li Han, Jian-Ming Zhou, De-Qiang Huang, Nong-Hua Lv
Serum alpha-fetoprotein (AFP) levels elevated in benign liver diseases (BLD) represent a challenge in hepatocellular carcinoma (HCC) diagnosis. The present study aimed to develop a simple method to identify HCC in AFP-elevated liver diseases based on combining serum fluorescence and general clinical data. Serum specimens and clinical data were collected from 201 HCC and 117 BLD (41 liver cirrhosis, 76 chronic hepatitis) patients with abnormal serum AFP levels. Dual serum fluorescence (autofluorescence and cell-free DNA-related fluorescence) intensities were sequentially measured and expressed as 6 fluorescence indicators...
November 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29228622/comparison-between-liver-resection-and-liver-transplantation-on-outcomes-in-patients-with-solitary-hepatocellular-carcinoma-meeting-unos-criteria-a-population-based-study-of-the-seer-database
#8
Anli Yang, Weiqiang Ju, Xiaopeng Yuan, Ming Han, Xiaoping Wang, Zhiyong Guo, Xiaoli Wei, Dongping Wang, Xiaofeng Zhu, Linwei Wu, Xiaoshun He
Liver resection (LR) and liver transplantation (LT) are potential curative treatment methods for early hepatocellular carcinoma (HCC). However, it is controversial which treatment is more beneficial to patients with solitary HCC meeting the United Network for Organ Sharing (UNOS) criteria (single lesion, diameter≤50mm, no vascular invasion, no extrahepatic metastasis). We retrieved patients with solitary HCC meeting UNOS criteria diagnosed between 2004-2013 from the Surveillance Epidemiology and End Results (SEER) database...
November 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/29228221/oncogenic-potential-of-hepatitis-b-virus-subgenotype-d1-surpasses-d3-significance-in-the-development-of-hepatocellular-carcinoma
#9
Somenath Datta, Debanjali Dasgupta, Alip Ghosh, Suchandrima Ghosh, Alak Manna, Simanti Datta, Mitali Chatterjee, Abhijit Chowdhury, Soma Banerjee
Despite widespread distribution of HBV-genotype D, the clinical implications of its 9 subgenotypes (D1-D9) have not been well documented. Here, we have investigated the impact of two major circulating HBV/D-subgenotypes, D1 and D3 in Eastern India towards pathogenesis of liver disease progression to hepatocellular carcinoma (HCC). HBV-subgenotypes were determined using full-length genome sequences of HBV isolates from patients with chronic hepatitis B (CHB), liver cirrhosis (LC) and HCC. Impact of D1 and D3 on viral lifecycle and disease progression was assessed by several invitro assays...
December 8, 2017: Carcinogenesis
https://www.readbyqxmd.com/read/29228217/p19arf-inhibits-aggressive-progression-of-h-ras-driven-hepatocellular-carcinoma
#10
Dragana Kopanja, Akshay Pandey, Shuo Huang, Mohamed Rizwan Haroon Al Raheed, Grace Guzman, Pradip Raychaudhuri
Arf, a well-established tumor suppressor, is either mutated or downregulated in a wide array of cancers. However, its role in hepatocellular carcinoma (HCC) progression is controversial. Conflicting observations have been published regarding its expression in HCC. In this study, we provide clear genetic evidence demonstrating a protective role of p19Arf in hepatocarcinogenesis. Using Ras-induced mouse model, we show that p19Arf deficiency accelerates progression of aggressive HCC in vivo. To investigate the role of p14ARF in human liver cancers, we analyzed its expression in human HCC using immunohistochemistry...
December 8, 2017: Carcinogenesis
https://www.readbyqxmd.com/read/29221923/combination-of-neoadjuvant-transcatheter-arterial-chemoembolization-and-orthotopic-liver-transplantation-for-the-treatment-of-cirrhotomimetic-hepatocellular-carcinoma
#11
Peiman Habibollahi, Sara P Shamchi, Rashmi Tondon, Brett L Ecker, Terence P Gade, Stephen Hunt, Michael C Soulen, Emma E Furth, Matthew H Levine, Gregory Nadolski
PURPOSE: To examine differences in outcome and response of cirrhotomimetic (CMM) hepatocellular carcinoma (HCC) to a combination of bridging transcatheter arterial chemoembolization and orthotopic liver transplantation (OLT) compared with non-CMM HCC. MATERIALS AND METHODS: All patients with pathologically proven CMM HCC who underwent bridging transcatheter arterial chemoembolization before OLT between 2007 and 2013 (n = 23) were retrospectively compared with a control group of patients with pathologically proven non-CMM HCC (n = 46)...
December 5, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29221168/diagnosis-prognosis-and-bioinformatics-analysis-of-lncrnas-in-hepatocellular-carcinoma
#12
Meiyu Dai, Siyuan Chen, Xiaomou Wei, Xuan Zhu, Fang Lan, Shengming Dai, Xue Qin
This study aims to comprehensively analyze the diagnosis and prognosis of lncRNAs in hepatocellular carcinoma (HCC). From the Gene Expression Omnibus database, we screened out and analyzed the differently expressed lncRNAs and related mRNAs using bioinformatics methods. The expressions of lncRNAs were validated in tumor tissues, cell lines and the Cancer Genome Atlas database. At the same time, we also conducted an exploratory analysis on the diagnostic and prognostic ability of lncRNAs in HCC. In this study, we found that most of the targeted mRNAs promote the biological process of cell division, cellular component of nucleoplasm, molecular function of protein binding, which were significantly associated with 12 KEGG pathways...
November 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29218611/portal-hypertension-is-associated-with-poor-outcome-of-transarterial-chemoembolization-in-patients-with-hepatocellular-carcinoma
#13
Jin Woo Choi, Jin Wook Chung, Dong Ho Lee, Hyo-Cheol Kim, Saebeom Hur, Myungsu Lee, Hwan Jun Jae
OBJECTIVES: To determine whether clinically relevant portal hypertension (CRPH) influences outcome and whether it may serve as a prognostic marker in patients treated with transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). METHODS: One hundred and forty-seven patients underwent conventional TACE as a first-line treatment for a single HCC. CRPH was graded as 0, 1, or 2. The influence of CRPH, together with other factors, on local tumour progression (LTP) and overall survival (OS) were analysed using Cox proportional hazards regression...
December 7, 2017: European Radiology
https://www.readbyqxmd.com/read/29217359/impact-of-tumor-size-on-the-prognosis-of-hepatocellular-carcinoma-in-patients-who-underwent-liver-resection
#14
Chia-Yen Dai, Ching-Yeh Lin, Pei-Chien Tsai, Ping-Yi Lin, Ming-Lun Yeh, Chung-Feng Huang, Wen-Tsan Chang, Jee-Fu Huang, Ming-Lung Yu, Yao-Li Chen
BACKGROUND: Health burdens of hepatocellular carcinoma (HCC) are emerging quickly in the world, including in Taiwan. Surgical resection has been recognized as the first-line treatment for early tumors. This study aimed to investigate the prognostic risk factors for mortality and recurrence rate in Taiwan, which has a high prevalence of chronic viral hepatitis. METHODS: A total of 397 HCC patients receiving tumor resection were consecutively examined in central Taiwan from 2008 to 2014...
December 4, 2017: Journal of the Chinese Medical Association: JCMA
https://www.readbyqxmd.com/read/29215815/plasma-microrna-21-26a-and-29a-3p-as-predictive-markers-for-treatment-response-following-transarterial-chemoembolization-in-patients-with-hepatocellular-carcinoma
#15
Soon Sun Kim, Hyo Jung Cho, Ji Sun Nam, Hyun Ji Kim, Dae Ryong Kang, Je Hwan Won, Jinoo Kim, Jai Keun Kim, Jei Hee Lee, Bo Hyun Kim, Mi Young Lee, Sung Won Cho, Jae Youn Cheong
BACKGROUND: We investigated an association between the levels of plasma microRNA (miRNA)-21, -26a, and -29a-3p and treatment outcomes following transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). METHODS: A total of 198 patients with TACE-treated HCC were followed up for TACE refractoriness and liver transplantation (LT)-free survival. Pretreatment plasma miRNA-21, -26a, and -29a-3p levels were measured using quantitative real-time polymerase chain reaction...
January 1, 2018: Journal of Korean Medical Science
https://www.readbyqxmd.com/read/29211363/hierarchical-potential-differentiation-of-liver-cancer-stem-cells
#16
REVIEW
Wenfeng Zhang, Di Mu, Kai Feng
Hepatocellular carcinoma (HCC) is one of the most malignant tumors in Chinese people and offers poor prognosis. Tumor tissue, like normal tissue, is hierarchically differentiated. Thus, minor tumor cell populations able to differentiate, such as stem cells, sustain tumor self-renewal and proliferation. The fact that liver cancer stem cells (CSCs) with different surface markers appear heterogeneous with respect to oncogenesis and drug resistance indicates that subpopulations of surface markers preserve the hierarchical potential of differentiation during proliferation, deterioration and relapse...
October 2017: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
https://www.readbyqxmd.com/read/29209739/hepatocarcinogenesis-and-li-rads
#17
Kazim H Narsinh, Jennifer Cui, Demetri Papadatos, Claude B Sirlin, Cynthia S Santillan
Hepatocarcinogenesis is a multi-step process characterized by progressive cellular and molecular dedifferentiation of hepatocytes and culminating in the emergence of hepatocellular carcinoma (HCC). Knowledge of hepatocarcinogenesis is important because familiarity with the associated imaging features can lead to improved diagnosis of HCC at its early stages. The article reviews the alterations that accumulate leading to HCC result in abnormal imaging features, many of which are included in LI-RADS v2017 as major and ancillary features...
December 5, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/29209123/prediction-of-early-stage-hepatocellular-carcinoma-using-oncoscan-chromosomal-copy-number-aberration-data
#18
Ming-Chin Yu, Chao-Wei Lee, Yun-Shien Lee, Jang-Hau Lian, Chia-Lung Tsai, Yi-Ping Liu, Chun-Hsing Wu, Chi-Neu Tsai
AIM: To identify chromosomal copy number aberrations (CNAs) in early-stage hepatocellular carcinoma (HCC) and analyze whether they are correlated with patient prognosis. METHODS: One hundred and twenty patients with early-stage HCC were enrolled in our study, with the collection of formalin fixed, paraffin-embedded (FFPE) specimens and clinicopathological data. Tumor areas were marked by certified pathologists on a hematoxylin and eosin-stained slide, and cancer and adjacent non-cancerous tissues underwent extraction of DNA, which was analyzed with the Affymetrix OncoScan platform to assess CNAs and loss of heterozygosity (LOH)...
November 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29204978/role-of-glypican-3-in-the-growth-migration-and-invasion-of-primary-hepatocytes-isolated-from-patients-with-hepatocellular-carcinoma
#19
Mauro Montalbano, Cristiana Rastellini, Joshua T McGuire, Janika Prajapati, Ali Shirafkan, Renza Vento, Luca Cicalese
BACKGROUND: Recently, Glypican-3 (GPC3) has been identified as a potential hepatocellular carcinoma (HCC) diagnostic and/or therapeutic target. GPC3 has been found to be up-regulated in HCC and to be absent in normal and cirrhotic liver. As yet, however, the molecular characteristics of GPC3 and its role in HCC cell physiology and development are still undefined. METHODS: Human hepatocyte cultures were established from 10 HCC patients. Additional liver samples were obtained from 5 patients without cirrhosis and/or HCC...
December 4, 2017: Cellular Oncology (Dordrecht)
https://www.readbyqxmd.com/read/29197520/effects-of-pirfenidone-in-acute-and-sub-chronic-liver-fibrosis-and-an-initiation-promotion-cancer-model-in-the-mouse
#20
Oleksii Seniutkin, Shinji Furuya, Yu-Syuan Luo, Joseph A Cichocki, Hisataka Fukushima, Yuki Kato, Hiromi Sugimoto, Tomoko Matsumoto, Takeki Uehara, Ivan Rusyn
Liver fibrosis results from chronic tissue damage and excessive regeneration with accumulation of extracellular matrix proteins; it is a precursor of liver cirrhosis and hepatocellular carcinoma. Liver fibrosis treatments are primarily directed at inflammation, with few options to combat fibrogenesis. Pirfenidone is a drug approved for idiopathic pulmonary fibrosis and this study was focused on anti-fibrotic and anti-cancer potential of pirfenidone in the liver of male B6C3F1/J mice. In a dose-finding study, mice were treated with CCl4 (0...
November 29, 2017: Toxicology and Applied Pharmacology
keyword
keyword
14664
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"